Thymus-derived peptides in the treatment of viral chronic hepatitis

Digestive Diseases

Volumn 14, Issue 6, 1996, Pages 362-370

  Naylor, Paul H ^a   Mutchnick, Milton G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Peptides; Thymic; Thymic extracts; Thymosin; Viral chronic hepatitis

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; THYMUS HORMONE;

CHRONIC HEPATITIS; CLINICAL TRIAL; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOLOGY; REVIEW;

ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPATITIS B; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA; THYMUS HORMONES;

EID: 0030280708     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000171570     Document Type: Article

References (41)

1. Maddrey WC: Chronic hepatitis. Dis Month 1993:39:74-90.
2. Peters M: Mechanism of action of Interferons. Semin Liver Dis 1989: 9:235-239.
3. Katkov WN, Dienstag JL: Prevention and therapy of viral hepatitis. Semin Liver Dis 1991:11:165- 174.
4. Dusheiko GM, Zuckerman AJ: Treatment of chronic viral hepatitis. J Antimicrob Chcmother 1993:32: 107-120.
5. Peters M, Veirline J, Gershwin E, Milich D, Chisari FV, Hoofnagle JH: Immunology and the liver. Hepatology 1991:13:977-994.
6. Mutchnick MG, Ehrinpreis MN, Kinzie JL, Peleman RP: Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Res 1994:24:245-257.
7. Low TLK, Goldstein AL: Thymo-sins: Structure, function and therapeutic applications. Thymus 1984: 6:27-34.
8. Schulof RS, Naylor PH, Sztein MB, Goldstein AL: Thymic physiology and biochemistry. Adv C'lir. Chem 1987:26:203-292.
9. Goldstein AL, Guiha A, Zalz MM, Hardy M, White A: Purification and biological activity of thymosin: A hormone of the thymus gland. Proc Natl Acad Sci USA 1972:69:1800-1812.
10. Low TLK, Thurman M, McAdoo M, McClure JE, Rossio JL, Naylor PH, Goldstein AL: The chemistry and biology of thymosin. J Biol Chem 1979;254:981-986.
11. Serrate SA, Schulof TRS, Leondari-das L, Goldstein AL, Sztein MB: Modulation of human natural killer cell cytotoxic activity, lymphokinc production, and interleukin 2 receptor expression by thymic hormones. J Immunol 1987:139:2338-2343.
12. Svedersky LF, Hui A, May L, McKay P, Siebbing N: Induction and augmentation of mitogen induced interferon production in human peripheral blood lymphocytes by desacctyl thymosin a I. Eur J Immunol 1982:12:244-247.
13. Sztein MB, Serrate SA, Goldstein AL: Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA 1986:83: 6107-6111.
14. Baxevanis CN, Rectos GJ, Perez S, Kokkinopoulos D, Papamichail M: Immunorcgulatory effects of fraction 5 thymus peptides. I. Thymosin Tal enhances while thymosin pj suppresses the human autologous and allogeneic mixed lymphocyte reaction. Immunopharmacol-ogy 1987;13:133-141.
15. Mutchnick MG, Missirian A, Johnson AG: Lymphocyte cytotoxicity in human liver disease using rat hépatocyte monolayer cultures. Clin Immunol Immunopathol 1980; 16: 423-437.
16. Mutchnick MG, Prieto JA, Schaffner JA, Weller FE: Thymosin modulation of regulatory T cell function. Clin Immunol Immunopathol 1982: 23:626-633.
17. Mulchnick MG, Schaffner JA, Prieto JA, Weller FE, Goldstein AL: Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis. Dig Dis Sei 1983;28:328-334.
18. Zav’yalov VP, Denesyuk AI, Zav'yalova GA: Theoretical analysis of conformation and active sites of interferons. Immunol Lett 1989:22: 173-181.
19. Moody TW, Fagarasan M, Zia F, Cesnjaj M, Goldstein AL: Thymosin at down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res 1993:53:5214-5218.
20. Moshicr JA, Mutchnick M, Dosescu J, Holtz T, Akkory S, Mahakla K, Skunca M, Naylor PH: Thymosin ui inhibits anchorage-independent growth of hepatitis B transfected hepatocellular carcinoma cells. Gastroenterology 1994; 106: A946.
21. Eichbcrg JW, Seef TLB, Lawlor PL, Bushell-Balcs Z, Ishak K, Hoofnagle JH, Goldstin AL, Langloss JM: Effect of thymosin immuno-stamutation with and without corticosteroid immunosuppression on chimpanzee hepatitis B carriers. J Med Virol 1987:21:25-37.
22. Gerin JL, Korba BE, Cote PJ, Tennant BC: A preliminary report of a controlled study of thymosin alpha I in the woodchuck model of hepad-navirus infection: in Black T, el al (eds): Innovations in Antiviral Development and the Detection of Virus Infection. New York. Plenum Press. 1992, pp 121-123.
23. Dabrowski MP, Dabrowski-Bern-stein BK, Brzosko WJ, Babiuch L, Kassur B: Immunotherapy of patients with chronic virus B hepatitis. I. Maturation of human T lymphocytes under influence of calf thymic hormone. Clin Immunol Immuno-palhol 1980:16:297-307.
24. Skotnicki A, Dabrowska-Bemstein BK, Dabrowski MP, Gorski A, Czamecki J, Alekxandrowice J: Biological properties and clinical use of calf thymus extract TFX-Polfa: in Goldstein AL (ed): Thymic Hormones and Lymphokincs. New York. Plenum Press. 1984. pp545-564.
25. Skotnicki AB: Therapeutic applications of calf thymus extract (TFX). Med Oncol Tumor Pharmacolher 1989:6:31-43.
26. Zeman K, Dwomiak D, Tchorzew-ski H, Pokcam L, Majcwska E: Effect of thymic extract on allogenic MLR and mitogen-induced responses in patients with chronic active hepatitis B. Immunol Invest 1991;20:545-555.
27. Romeo F, Palmisano L, Arcoria D: Thymostimulin in the treatment of hepatitis B surface antigen-positive chronic active hepatitis. Arzneimit-telforschung 1987;37:450-456.
28. Zhang DF, Chen GM, Fan C, Mi Z-D: Suppressor cell function and thy-mopeptide therapy in viral hepatitis B. Chin Med J 1986:99:791-798.
29. Sheng S: Use of porcine thymic extract and thymic peptide in treatment of chronic hepatitis B and fulminant viral hepatitis: in Goldstein A (ed): Thymic Hormones and Lym-phokines. New York, Plenum Press, 1984, pp 94-102.
30. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, Waggoner JG, Hoofnagle JH, Shafrilz DA: Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hcpatologv 1991:14:409-415.
31. Mutchnick MG, Cummings GD, Hoofnagle JH, Shafritz DA: Thymosin: An innovative approach to the treatment of chronic hepatitis B; in Goldstein AL. Garaci E (cds): Combination Therapies. New York. Plenum Press. 1992. pp 149-157.
32. Mutchnick MG, Jaurcqui JL, Shafritz DA: Sustained response to thymosin therapy in patients with chronic hepatitis B: in Goldstein AL. Garaci E (cds): Combination Therapies. New York. Plenum Press, 1992. pp 217-223.
33. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C: Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-274.
34. Thomas HC: The hepatitis B virus and the host response. J Hepatol 1990;11(suppl):83-89.
35. 2 interferon treatment of HBsAg. HBeAb. HBV DNA positive chronic active hepatitis (abstract). Hcpatology 1992:16:67.
36. Andreone P, Cursaro C, Gramenzi A, Miniera R, Manzin A, Severini R, Franzone JS, Clementi M, Spro-vieri G, Gasbarrini G: Preliminary results of thymosin al vs. IFN-a treatment in patients with HBsAg negative and HBV-DNA positive chronic active hepatitis, lnt J Imniu-nother 1993:124:201-205.
37. 1 vs. IFN-α treatment in patients with HBsAg and HBeAb positive chronic active hepatitis (abstract 121). World Congress of Gastroenterology. 1994.
38. Rasi G, Mutchnick MG, Divirgilio D, Picrimarchi P, Sinibaldi-Valle-bone P, Colella F, Favalli C, Garaci E: Combination low dose Ivmpho-blastoid interferon (L-IFNa) and thymosin ul (Tal) therapy in the treatment of chronic hepatitis B (abstract). Hepatology 1994:20:811.
39. Rezakovic I, Zavaglia C, Bottelli R, Ideo G: A pilot study of thymosin alpha 1 therapy in chronic active hepatitis C (abstract). Hcpatology 1993:18:252.
40. Sherman KE, Sjogren MIL, Creager RL, Freeman S, O'Brear J, Noot S, Davis G: Hepatitis C RNA response to combined therapy with thymosin ai and interferon (abstract). Hcpatology 1994;20:444.
41. Mutchnick MG, Lindsay KL, Schit TER, Cummings GD, Appelman HD: Thymosin Ui treatment of chronic hepatitis B: A multicenter, randomized. placebo-controlled, double blind study (abstract). Gastroenterology 1993; 108:A1127.